A new cellular therapy approach targets not just cancer cells themselves, but also the immunosuppressive molecules and cells that allow tumors to evade immune attack. Scientists have engineered T cells with a novel receptor that recognizes PD-L1 (programmed death-ligand 1), a key immune-suppressing molecule found on both tumor cells and surrounding immune cells within the tumor microenvironment.

What Is PD-L1 and Why Does It Matter in Cancer?

PD-L1 is a molecular "off switch" that tumors and their surrounding cells use to dampen anti-tumor immune responses. For more than a decade, researchers have explored ways to overcome this suppressive state by harnessing naturally occurring "anti-regulatory" T cells that recognize antigens derived from immunosuppressive molecules. The breakthrough here is translating that knowledge into a practical cellular therapy.

Previous research showed that PD-L1-specific T cells exist naturally in both healthy donors and cancer patients, and can eliminate PD-L1-expressing tumor and immune cells. More encouragingly, a peptide vaccination combined with anti-PD-1 therapy produced promising responses in patients with metastatic melanoma. This success raised a compelling question: could these cells be engineered into a dedicated cellular therapy ?

How Scientists Built This New Therapy?

Researchers at the National Center for Cancer Immune Therapy in Denmark took a multi-step approach to create what they call PDL101-TCR-T cells. First, they isolated a monoclonal T-cell population specific for a PD-L1-derived peptide from a patient with breast cancer and reconstructed the T-cell receptor (TCR) responsible for recognizing it. A TCR is the protein on T cells that allows them to identify and attack specific targets.

Using a non-viral CRISPR-Cas9-based strategy, the team replaced the endogenous TCR of primary T cells with the newly identified PDL101-specific TCR, thereby redirecting their specificity. The engineered PDL101-TCR-T cells proved fully functional and antigen-responsive, showing potent inflammatory responses when exposed to their target and efficiently killing target cells presenting the PD-L1 epitope.

How Does This Dual-Targeting Strategy Work?

A key advantage of targeting PD-L1 is that it is not restricted to cancer cells alone. It is also expressed by multiple immunosuppressive cell populations within the tumor microenvironment, including tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs). This opened the possibility of a dual-targeting strategy.

In laboratory experiments, the engineered T cells selectively recognized and killed PD-L1-positive cancer cell lines while sparing their PD-L1-negative sister cell lines. Importantly, they also reacted to suppressive myeloid populations resembling TAMs and M2-like cells. This suggests that these T cells may not only attack the tumor directly but also help dismantle the surrounding immunosuppressive environment.

• Direct tumor attack: The engineered cells recognize and kill cancer cells expressing PD-L1, targeting the tumor itself.
• Immune environment remodeling: The cells also target immunosuppressive myeloid cells within the tumor microenvironment, potentially "inflaming" the tumor and promoting broader anti-tumor immune responses.
• Sparing healthy cells: The cells selectively target PD-L1-positive populations while leaving PD-L1-negative cells unharmed, reducing off-target effects.

"Rather than targeting a single malignant population, PD-L1-specific TCR-T cells could 'inflame' the tumor microenvironment and thereby promote broader anti-tumor immune responses," explained Thomas Hvidkjær Lisle, a postdoctoral researcher at Aarhus University.

Thomas Hvidkjær Lisle, Postdoctoral Researcher, Aarhus University

What Safety and Efficacy Challenges Remain?

During CRISPR-Cas9 editing, researchers observed a relatively low integration and expression rate of the transgenic TCR compared to traditional viral transduction methods. This led them to ask whether the engineered T cells could be boosted by vaccination. Indeed, the proportion of PDL101-specific T cells increased markedly after repeated stimulations with peptide-loaded dendritic cells in laboratory settings. While this was only a proof-of-concept, it suggests a potential strategy of combining adoptive TCR-T-cell therapy with peptide vaccination to expand and sustain transferred cells in patients.

Safety remains an important consideration with all therapies targeting broadly expressed immune molecules. PD-L1 is not exclusive to tumors, and previous PD-L1-targeted CAR-T approaches have raised concerns about on-target, off-tumor toxicity. However, this approach differs in an important way: instead of using an artificially engineered CAR (chimeric antigen receptor), researchers used a naturally derived, MHC-restricted TCR specificity. The team speculates that this physiological recognition mechanism may provide a higher activation threshold and potentially a more favorable safety profile, although this will need careful evaluation in future preclinical studies.

What Does This Mean for Cancer Patients?

This research represents the first steps toward translating the biology of anti-regulatory PD-L1-specific T cells into a defined cellular therapy. By combining naturally occurring TCR specificity with precise CRISPR-based engineering, scientists showed that PD-L1-specific TCR-T cells can target both tumor cells and immunosuppressive cells relevant within the tumor microenvironment. This platform lays the groundwork for further research into immune modulatory cellular therapies designed not only to attack cancer directly but also to reshape the environment that allows tumors to persist.

The findings align with a broader shift in cancer medicine toward increasingly sophisticated cellular therapies. At the 2026 ASCO Breakthrough Annual Meeting, global experts highlighted how rapidly cancer treatment continues to evolve, with cellular therapy and precision oncology reshaping care across both solid tumors and hematologic malignancies. The field is moving toward treatments that are both more biologically precise and more personalized, tailoring therapy based on the unique biology driving each patient's cancer.

While these engineered T cells are still in early research stages and have not yet been tested in human patients, the dual-targeting approach offers a conceptually novel way to overcome one of cancer's most effective immune-evasion strategies. Future clinical trials will determine whether this laboratory promise translates into meaningful benefits for patients with melanoma, breast cancer, and other malignancies expressing PD-L1.